UroAlerts - Prostate Cancer Weekly

April 14, 2026

Videos

Peer-to-Peer Clinical Conversations

NRG-GU006 Trial for Post-Prostatectomy Radiation Therapy - Daniel Spratt

Daniel Spratt

Daniel Spratt presents NRG GU006/BALANCE trial results with Jeff Michalski, demonstrating PAM50 molecular subtypes as the first prospectively validated predictive biomarker guiding hormone therapy decisions in recurrent prostate cancer.

Phase III PSMAfore Trial: Final Survival and Safety Data in mCRPC, Journal Club - Rashid Sayyid & Zachary Klaassen

Zachary Klaassen

Rashid Sayyid and Zachary Klaassen discuss the final overall survival analysis of the PSMAfore trial comparing lutetium-PSMA-617 versus ARPI switch in taxane-naive mCRPC patients.

Beyond the Abstracts

ESUR: Opportunities for PSMA-PET/CT and Whole-Body MRI in Advanced Prostate Cancer - Beyond the Abstract

4K Density: Adjusting the 4Kscore for Prostate Volume to Improve Risk Stratification of Clinically Significant Prostate Cancer in Men Undergoing Prostate Biopsy - Beyond the Abstract

Conference Coverage

PSMA and Beyond 2026: Clinical Trial Updates: PEACE-6 PR Trial

EAU 2026: State of the Art Lecture: Why Are Germline and Somatic Alterations in Prostate Cancer Important?

EAU 2026: Closing the Knowledge Gap to Inform Policy Decision-Making: Health-Related Quality of Life and Health Anxiety in Men Undergoing Screening for Prostate Cancer

ASCO GU 2026: Association of a Post-Prostatectomy Digital Pathology-Based MMAI Biomarker with Nodal and Extrapelvic Metastasis on PET/CT at the Time of Biochemical Recurrence and Event-Free Survival Following Salvage Radiotherapy

ASCO GU 2026: TulmiSTAR-01: A Phase I/II Dose Optimization Study of Tulmimetostat in Combination with Luxdegalutamide Versus SOC in Patients with Progressive mCRPC

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

A Cost-Analysis and Micro-Costing Study of the Man Van Project: Comparing Prostate-Specific Antigen Testing Via a Nurse-Led Mobile Service with Primary Care - Beyond the Abstract

Pain and health-related quality-of-life outcomes with darolutamide in metastatic hormone-sensitive prostate cancer (ARANOTE): secondary and exploratory analyses of a multicentre, randomised, placebo-controlled, phase 3 trial.

Efficacy and safety of darolutamide in combination with androgen deprivation therapy and docetaxel in European patients from the phase 3 ARASENS trial.

Development of a Prognostic Prediction Model for Clinically Significant Prostate Cancer Based on Lesion Zone and Apparent Diffusion Coefficient Value Quantification - Beyond the Abstract

Cost-effectiveness of an artificial intelligence predictive model for guiding androgen deprivation therapy in intermediate-risk prostate cancer.

OncoEducate: A Pilot Study of Generative AI to Enhance Patient-Clinician Communication in Genitourinary Cancer Care.

Extended Follow-up from the Stereotactic Body Radiotherapy for High-risk Localized Carcinoma of the Prostate (SHARP) Consortium: Updated Analysis of 440 Patients.

Integrating Genomic Prostate Score with Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores to Predict Biochemical Recurrence after Radical Prostatectomy.

Hypo fractionated Versus Conventional IMRT in Unfavorable Intermediate- and High-Risk Prostate Cancer: A Phase II Comparative Study of PSA Kinetics, Dosimetric and Toxicity Outcomes.

Genome-wide methylome profiling of cell-free DNA enables prognostication of patients with castration-resistant prostate cancer.

Identifying preferences for prostate cancer screening among American Indian men (Project AIMEPCCo): Protocol for a discrete choice experiment.

Evaluating an AI-driven Triaging Workflow for MRI-based Clinically Significant Prostate Cancer Diagnosis: A Simulation Study.

Integrative molecular analyses of lineage identity and morphology in aggressive variant prostate cancer.

Evaluating MRI findings and biopsy strategies to maximize detection of grade progression in men on active surveillance for prostate cancer.

CREB5 regulates stem cell-like transcriptional programs to enhance tumor progression in prostate cancer.

Changing trends in androgen deprivation therapy prescribing for prostate cancer in England, 2015-2024.

The Proposed Introduction of a Prostate Cancer Screening Program in Germany: Procedure, Necessary Studies before Implementation, Benefits, and Risks.

Novel Theranostic Targets for Prostate Cancer Beyond Prostate-Specific Membrane Antigen.

Castration Resistance Accelerates Prostate Cancer Kinetics.

Genomic Prostate Score (GPS) as a Prognostic Biomarker in Patients With Localized Prostate Cancer Undergoing Focal Therapy.

Stereotactic Body Radiation Therapy (SBRT)-Induced 68Ga-PSMA PET Bone Flare.

Trends and Disparities in the Use of Next-Generation Sequencing in Patients With Cancer in the United States.

Advances in Androgen Deprivation Therapy-Sparing Strategies: Ongoing Studies in Metastatic Castration-Sensitive Prostate Cancer.

Characterization of Clinically Significant Prostate Cancer in the Peripheral Zone Using Rapid B1-Insensitive MR Fingerprinting.

Moderate hypofractionation: long-term toxicity results of prostate bed radiotherapy (FRAME-PROSTATE).

Leveraging Population-Level and Multipayer Claims Data to Estimate Changes in Prostate Cancer Screening at the Small-Area Level.

Mediation analysis of adherence to pelvic floor muscle training and weekly self-monitoring on urinary symptoms in men with localized prostate cancer: A secondary analysis of the Prostate Cancer-Patient Empowerment Program (PC-PEP) randomized controlled tr

Clinical Characteristics and Predictive Factors of Symptomatic Skeletal Events in Patients With Metastatic Castration-Sensitive Prostate Cancer Treated With Denosumab.

Dosimetric comparison of implantable rectal spacers for low-dose-rate prostate brachytherapy.

Cost-effectiveness of PSMA-PET imaging technology in diagnosing and staging of prostate cancer: a systematic review.

The molecular pathology of prostate cancer: an update for practising pathologists.

Optimizing ChatGPT: Applying prompt engineering to frequently asked questions in urologic oncology.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC